Frequency Therapeutics to Present at Cowen & Company 39th Annual Health Care Conference


Frequency Therapeutics, a clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), today announced that Chris Loose, Ph.D., Co-Founder and Chief Scientific Officer, will provide a corporate update at the Cowen & Company 39th Annual Health Care Conference taking place March 11-13 at the Marriott Copley Place Hotel in Boston, MA.

Presentation details are as follows:

Date: Monday, March 11, 2019 Time: 9:00 “ 9:25am ET Location: MIT, 3rd floor

ABOUT PCA REGENERATION Founded by pioneers in the field of regenerative medicine and drug delivery technology, Frequencys Progenitor Cell Activation (PCA) Regeneration platform uses a combination of small molecules to stimulate progenitor cells within the body to repair diseased or damaged tissue. This technology enables native tissue regeneration without modifying genes or removing cells from the body. This avoids the potential safety risks of genetic engineering and the manufacturing challenges of traditional cell therapy. This approach has been validated both in animal and human cell models as well as in a human clinical trial with the potential for broad application across many therapeutic areas.

ABOUT FREQUENCY THERAPEUTICS Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency enables disease modification without the complexity of genetic engineering. Our ground-breaking therapy uses a proprietary combination of small-molecule drugs that induce progenitor cells to multiply and create new cells. While Frequencys lead program targets hearing restoration, our PCA Regeneration platform has the potential to touch upon a wide breadth of disease indications.

Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications
[email protected]